HMGB1 and cancer: This paracrine HMGB1-TLR2/4-sCLU pathway apparently may also be elicited by other current anti-cancer compounds, because gemcitabine, taxol, Ara-C, doxorubicin, cisplatin, etoposide and carboplatin could all readily induce HMGB1 release from dying tumor cells.